SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma rises on the buzz of plan to file new drug application with USFDA

31 Jul 2015 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs 819.55, up by 5.25 points or 0.64% from its previous closing of Rs 814.30 on the BSE.

The scrip opened at Rs. 822.00 and has touched a high and low of Rs. 823.20 and Rs. 812.40 respectively. So far 105530 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.70 on 07-Apr-2015 and a 52 week low of Rs. 743.25 on 08-Aug-2014.

Last one week high and low of the scrip stood at Rs. 839.90 and Rs. 810.05 respectively. The current market cap of the company is Rs. 197043.90 crore.

The promoters holding in the company stood at 54.71% while Institutions and Non-Institutions held 31.51% and 13.78% respectively

Sun Pharmaceutical Industries is reportedly likely to file application for a new drug with the US Food and Drug Administration (USFDA) in next two to three years. The company's research arm Sun Pharma Advanced Research Company (SPARC) is currently working on three new drugs that are currently under clinical trial stage.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Sun Pharma Inds. Share Price

1679.85 10.65 (0.64%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×